Clinical Trials Logo
  1. Home
  2. Liver Steatoses
  3. NCT06443723

Metabolic Dysfunction Associated Fatty Liver Disease in Long-Term Cholecystectomy Patients

Liver Steatoses Clinical Trial

Official title:
Metabolic Dysfunction Associated Fatty Liver Disease in Long-Term Cholecystectomy: A Cross-sectional Case-control Study

Clinical Trial Summary

The aim of this study was to examine the association between metabolic associated fatty liver disease (MAFLD) in participants who had undergone cholecystectomy and those who had not undergone cholecystectomy. MAFLD is defined as hepatic steatosis(with ultrasonography) entity in addition to the presence of overweight or obesity, diabetes mellitus, or evidence of metabolic dysfunction. In this way, the long-term effects of cholecystectomy surgeries, which are commonly performed in the society and thought to be harmless, will be evaluated.

Clinical Trial Description

Cholecystectomy is known to be a harmless operation with low perioperative mortality and morbidity. However, the unexplained increase in metabolic disorders in cholecystectomy patients has led to the need for further investigation of cholecystectomy patients. Non-alcoholic fatty liver disease is an important health problem with an average prevalence of 25% worldwide and serious hepatic and systemic complications. The aim of this study was to examine the association of cholecystectomy with metabolic dysfunction associated fatty liver disease (MAFLD), which is an important public health problem in the long-term. This case-controlled cross-sectional study was planned to evaluate the relationship between patients who had undergone cholecystectomy with MAFLD. MAFLD is defined as hepatic steatosis entity in addition to the presence of overweight or obesity, diabetes mellitus, or evidence of metabolic dysfunction. The study included 86 participants with cholecystectomy and 63 participants without cholecystectomy. It was planned to compare the participants according to the diagnostic criteria for MAFLD (with or without MAFLD). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06443723
Study type Interventional
Source Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Contact
Status Completed
Phase N/A
Start date November 1, 2023
Completion date April 30, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03542578 - Diagnosis of Fatty Liver With Outpatient Ultrasound
Active, not recruiting NCT04682600 - The Sonic Incytes Liver Incytes System, Evaluation of Liver Fibrosis and Steatosis Versus MRE and MRI PDFF N/A
Not yet recruiting NCT05884723 - Preoperative Ketogenic Diet for Reduction of Hepatic Steatosis N/A
Not yet recruiting NCT05790057 - Subclinical Cardiovascular Changes in NAFLD Patient (Predictive Value of Speckle Tracking Echocardiography )
Completed NCT04579874 - Clinical Performance of LIVERFASt Test Compared w/ Liver Biopsy in Patients w/ NAFLD. N/A
Completed NCT05224037 - Comparative Efficacy of Liver Fibrosis and Steatosis Assessment With Fibroscan and iLivTouch N/A
Recruiting NCT06111859 - Effectiveness of Ultrasound in Liver Stiffness and Fat Quantification N/A
Active, not recruiting NCT06103175 - Observational and Prospective Study of Hepatic Steatosis and Related Risk Factors Using Ultrasound and Artificial Intelligence
Recruiting NCT03699228 - China Health Big Data
Completed NCT03342703 - Correlation of Ultrasound Based Measurements of Liver Stiffness and Steatosis With MRI